Premium
Neurotrophins In Diabetic Neuropathy
Author(s) -
Fernyhough P.
Publication year - 2000
Publication title -
journal of the peripheral nervous system
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1
H-Index - 67
eISSN - 1529-8027
pISSN - 1085-9489
DOI - 10.1046/j.1529-8027.2000.abstracts-7.x
Subject(s) - neurotrophin , neurotrophic factors , nerve growth factor , medicine , diabetic neuropathy , trk receptor , neuroscience , clinical trial , diabetes mellitus , bioinformatics , psychology , endocrinology , biology , receptor
The recent Genentech/Roche sponsored FDA phase III clinical trial of nerve growth factor (NGF) for the treatment of diabetic neuropathy failed. The aim of this talk is to discuss the reasons for this failure and based upon the lessons learned identify if there remain any other viable avenues for studies on neurotrophins in diabetic neuropathy. The presentation will briefly introduce the basic biology of the neurotrophins and their putative role in the aetiology and/or treatment of diabetic neuropathy. Some details of the NGF clinical trials will be presented and reasons for failure assessed. The main part of the talk will focus on future strategies for neurotrophin work with an emphasis on the possible roles of neurotrophin‐3 and brain‐derived neurotrophic factor. Alternative approaches based upon regulation of endogenous neurotrophin expression and use of neurotrophin trk receptor agonists will also be discussed. The aim of the talk is to show that lessons learned from the failed NGF trial should lead to a re‐invigoration of studies directed at determining alternative methods for optimising neurotrophic support of sensory neurones in diabetes.